Similarly, in 2019, Sesisto et al. selected another AChE inhibitor with brain-region selectivity and clinically approved drugs for AD [114], rivastigmine, and designed a new class of multitarget H2S-donating compounds (Figure 21) by combining it with two natural products, such as sulforaphane (SFN) and erucin (ERN), endowed both with antioxidant and neuroprotective effects [115]. This evidence concerns the gene ACHE and Alzheimer disease.